Phone: 888-558-5227

651-644-8424 Email: getinfo@lktlabs.com

888-558-7329 Fax:

Web: lktlabs.com

## **Product Information**

Product ID D0005

CAS No. 1195768-06-9

Chemical Name N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,

3-thiazol-4-yl]-2-fluorophenyl]-2,

6-difluorobenzenesulfonamide; methanesulfonic acid

Synonym

Formula  $C_{23}H_{20}F_3N_5O_2S_2 \cdot CH_3SO_3H$ 

Formula Wt. 615.67

**Melting Point** 

Purity ≥98%

Solubility soluble in DMSO

## **Pricing and Availability**

Bulk quanitites available upon request

Product ID	Size	List Price
D0005	5 mg	\$68.30
D0005	25 mg	\$152.30
D0005	100 mg	\$362.30

Store Temp -20°C Ship Temp Ambient

Description Dabrafenib is a reversible kinase inhibitor with anticancer chemotherapeutic activity. This compound is selective primarily for

mutant (V600E) B-Raf, but has also inhibited tumor growth in cells expressing other B-Raf mutants (V600K, V600D) and WT B-Raf. Dabrafenib is partially active against c-Raf as well. Dabrafenib is an ATP-competitive inhibitor that has been approved for clinical use in the treatment of unresectable or metastatic melanomas; it is also being examined for treatment of brain metastases

and other cancers. This compound has a very high oral bioavailability.

References Ballantyne AD, Garnock-Jones KP. Dabrafenib: First Global Approval. Drugs. 2013 Jul 24. [Epub ahead of print] PMID: 23881668.

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. PMID: 23617957.

Klinac D, Gray ES, Millward M, et al. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol. 2013;3:54. PMID: 23515890.

Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65. PMID: 22735384.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.